Daniel Passeri compensation by year
Cue Biopharma Summary Compensation Table · all 9 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Salary | $325,000 | $345,000 | $395,000 | $501,154 | $530,974 | $747,507 | $604,824 | $492,910 | $240,504 |
| Bonus | $81,218 | $103,500 | $187,625 | $244,625 | $239,050 | $234,637 | $0 | $186,660 | $0 |
| Stock awards | — | $0 | $0 | $2,844,000 | $0 | $0 | $0 | $0 | $0 |
| Option awards | $0 | $381,163 | $610,225 | $2,246,235 | $1,046,053 | $388,130 | $2,407,500 | $711,195 | $336,555 |
| Non-equity incentive | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $4,153 | $4,195 | $5,764 | $5,772 | $4,680 | $3,576 | $3,156 | $3,156 | $849,124 |
| Total | $406,218 | $833,858 | $1,198,614 | $5,841,786 | $1,820,756 | $1,373,850 | $3,015,480 | $1,393,921 | $1,426,183 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cue Biopharma, Inc. DEF 14A filed March 16, 2026, accession 0001193125-26-108301, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Cue Biopharma, Inc. filed document, accession 0001193125-26-108301. Every figure is read from that document and cited to the page and table it appears in. Filed March 16, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 81,000 | — | $3.21 |
| Option | 375,000 | — | $0.72 |
| Option | 337,500 | — | $0.98 |
| Option | 200,000 | — | $1.94 |
| Option | 12,500 | — | $5.01 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Cue Biopharma, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Cue Biopharma’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Daniel Passeri · this page | Former Chief Executive Officer | $1,426,183 |
| Matteo Levisetti | Former Chief Medical Officer | $1,219,364 |
| Usman Azam | President and Chief Executive Officer | $1,185,639 |
| Lucinda Warren | Chief Financial and Business Officer | $801,223 |
| Colin Sandercock | SVP, General Counsel and Secretary | $599,222 |
The full Cue Biopharma compensation record
free company briefThis page is one person within Cue Biopharma's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cue Biopharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.